Sign in

Biliary Atresia Treatment Market Projected to be Resilient by 2030

Biliary Atresia Treatment Market Projected to be Resilient by 2030

The Biliary Atresia Treatment Market is estimated to be valued at US$ 1,064.2 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Biliary atresia is a rare liver condition where the bile ducts outside and inside the liver are abnormally developed or damaged. It blocks the flow of bile from the liver to the small intestine which causes jaundice in infants. The main treatment for biliary atresia is portoenterostomy or kasai surgery which re-routes the bile flow. Medications are also used to manage symptoms, improve bile flow and prevent infections. Early diagnosis and treatment offers the best outcomes for infants with biliary atresia.

Market key trends:

One of the key trends driving the biliary atresia treatment market growth is increasing research & development activities to develop novel treatment therapies. Researchers are investigating stem cell therapies to regenerate new bile duct cells and better outcomes from kasai surgery. Companies are conducting clinical trials for new drug candidates such as exendin which targets cholangiocytes and may help improve bile flow. Other investigational therapies include gene therapy, nanomedicines and sphingosine-1-phosphate receptor modulators. Advancements in treatment will offer long term benefits for infants with biliary atresia and boost the market's growth over the forecast period.

Porter's Analysis

Threat of new entrants: The threat of new entrants in the Biliary Atresia Treatment Market is low due to high costs associated with R&D, clinical trials and obtaining regulatory approval.

Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of limited treatment options for biliary atresia.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to the presence of a large number of raw material suppliers and contract manufacturing organizations.

Threat of new substitutes: There is a low threat from substitutes as there are limited treatment alternatives available for biliary atresia currently.

Competitive rivalry: Intense due to the presence of many established players.

SWOT Analysis

Strength: Growing prevalence of biliary atresia and various pipeline drugs.

Weakness: High costs associated with clinical trials and lack of approved drugs. Limited awareness regarding biliary atresia.

Opportunity: Emerging economies provide lucrative growth opportunities. Increasing healthcare expenditure in developing nations.

Threats: Risk of failure in clinical trials. Stringent regulatory framework. Patent expiration of blockbuster drugs.

Key Takeaways

The global Biliary Atresia Treatment Market is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing prevalence of biliary atresia and extensive R&D activities.

Regionally, North America dominates the biliary atresia treatment market and is expected to continue its dominance over the forecast period owing to increasing healthcare expenditure and growing adoption of novel therapies.

Key players operating in the Biliary Atresia Treatment market are AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals.

Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more